Evidence map›Paper›PMID 40837115›Full record

ArticleNeuroscience applied2025

Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorder.

Asad Malik, Shannon N Millard, Ailidh Finlayson, Amy Beckenstrom, Abigail Abrahams, Dennis Hernaus, Stella D Voulgaropoulou, Therese van Amelsvoort, Daniel Umbricht, William J Martin and 14 more

Abstract read
In one paragraph

Article in Neuroscience applied, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Effort, timing and choice: a refined rodent effort choice task with excellent sensitivity to dopamine modulators.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Asad MalikP1vital Products Ltd., Wallingford, United Kingdom.
Shannon N MillardP1vital Products Ltd., Wallingford, United Kingdom.
Ailidh FinlaysonP1vital Products Ltd., Wallingford, United Kingdom.
Amy BeckenstromP1vital Products Ltd., Wallingford, United Kingdom.
Abigail AbrahamsP1vital Products Ltd., Wallingford, United Kingdom.
Dennis HernausDepartment of Psychiatry and Neuropsychology, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, Netherlands.
Stella D VoulgaropoulouDepartment of Psychiatry and Neuropsychology, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, Netherlands.
Therese van AmelsvoortDepartment of Psychiatry and Neuropsychology, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, Netherlands.
Daniel UmbrichtXperimed LLC, Basel, Switzerland.
William J MartinJohnson & Johnson Innovative Medicine, Beerse, Belgium.
Darrel J PembertonJohnson & Johnson Innovative Medicine, Beerse, Belgium.
Jane TillerJohnson & Johnson Innovative Medicine, Beerse, Belgium.
Anke SambethFaculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands.
Oliver GrimmDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany.
Michael M PlichtaDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany.
Andreas ReifDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany.
Charis StyliadisMedical Physics and Digital Innovation Laboratory, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Athanasia LiozidouLaboratory of Cognitive Neuroscience and Clinical Neuropsychology, The Scientific College of Greece, Athens, Greece.
Georgios PapazisisDepartment of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Victor PérezInstituto de Salud Mental, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain.
Matilde ElicesInstituto de Salud Mental, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain.
Karla V AllebrandtTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
Stephane PollentierMedicine, Boehringer Ingelheim International GmbH, Binger Straße 173, 55216 Ingelheim am Rhein, Germany.
Gerard R DawsonP1vital Products Ltd., Wallingford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aims of the Reward Task Optimisation Consortium (RTOC) study (Bilderbeck et al., 2020) were to explore the validity, reliability, and feasibility of a battery of reward processing tasks for the development of new treatments for anhedonia. We report our findings from the Grip Strength Effort Task (GSET), an effort-based decision-making task in which participants chose to either perform easy trials that required less physical effort for low monetary reward or hard trials that required more effort for potentially larger rewards. Thirty-seven participants with schizophrenia (SZ), 40 with major depressive disorder (MDD), and 59 age- and sex-matched healthy controls were administered the task across four European sites. 19% of participants (8.5% HC, 27% SZ, 27.5% MDD) were 'inflexible responders' who always chose hard trials irrespective of the reward amount. MDD participants showed less willingness to exert physical effort for high reward than controls, when inflexible responders were excluded, but no statistically significant differences were observed between SZ participants and controls. Across all participants, willingness to exert effort for high reward negatively correlated with measures of anhedonia. Inflexible responders exhibited higher depressive symptoms and higher anticipation of punishment than other participants. Forty-three participants performed the GSET again after 3-5 weeks and moderate-to-high test-retest reliability was observed. Minimal site effects confirmed operational feasibility of the task in multi-site studies. We conclude that the GSET can provide objective behavioural biomarkers of reward processing dysfunction, but further investigation is needed to understand inflexible responding and its implications on the task's design and interpretation.

Indexed as

AnhedoniaApathyDepressionEffort-based decision-making taskNegative symptomsReward processingSchizophrenia

Identifiers

PMID40837115
PMCPMC12362125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.